Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00965276 · ClinicalTrials.gov registry record
Relationship of pAKT to Survival in Patients With Node-Positive Breast Cancer
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 2,500
- Enrollment target
NCT00965276: Completed study, sponsored by National Cancer Institute (NCI).
NCT00965276 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 2,500 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00965276 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 2,500 participants
- Enrollment target
Study Summary
This study will examine the relationship of a protein called pAKT to survival of breast cancer patients with one or more positive axillary lymph nodes. Akt plays a role in cell survival, tumor formation, and the development of drug resistance. The study will use tumor tissue obtained from 2,000 patients enrolled in a National Surgical Adjuvant Breast and Bowel Project study that is evaluating whether adding the drug paclitaxel (Taxol (Registered Trademark)) to a treatment regimen of doxorubicin (Adriamycin (Registered Trademark)) and cyclophosphamide (Cytoxan (Registered Trademark)) improves disease-free survival and overall survival in patients with node-positive breast cancer. The current study will measure levels of pAkt in the tissues and correlate the results with clinical outcome to see if pAkt levels are associated with improved patient survival. ...
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,500 participants |
| Start Date | 2004-01-13 |
| Est. Completion | 2010-12-14 |
What the finished NCT00965276 record still lists
NCT00965276 is an observational study that tracks outcomes without assigning an intervention. Its 2,500 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT00965276 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00965276 about?
NCT00965276 is a clinical study titled "Relationship of pAKT to Survival in Patients With Node-Positive Breast Cancer". This study will examine the relationship of a protein called pAKT to survival of breast cancer patients with one or more positive axillary lymph nodes. Akt plays a role in cell survival, tumor formation, and the development of drug resistance. The study will use tumor tissue obtained from 2,000 pat...
What is the current status of trial NCT00965276?
This trial is currently completed. The enrollment target is 2,500 participants. The study started on 2004-01-13. Estimated completion is 2010-12-14.
Who is sponsoring clinical trial NCT00965276?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001160 · 2,500 participants
Studies on Tumors of the Thyroid
- NCT01904188 · 2,500 participants
Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate?
- NCT02257229 · 2,500 participants
Prospective Evaluation of Treatment for Clubfoot
- NCT02530658 · 2,500 participants
Next Generation Sequencing of Normal Tissues Prospectively in Pediatric Oncology Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI